Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT07090161

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Vanda Pharmaceuticals (from the registry)
Registry
  • NCT NCT07090161
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07090161. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-15 (actual); primary completion 2026-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Condition
Hypertension
Condition
Uncontrolled Hypertension
Intervention (Drug)
iloperidone
Intervention (Drug)
Placebo
Lead sponsor
Vanda Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07090161
Content hash
843696df29805074454faa40faa423b1cf0e86f717f03196b0cd8bb2e1691bec